Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-κB and MMP-9 activation

Yi,Wan-Rong; Li,Zong-Huan; Qi,Bai-Wen; Ernest,Mendame  Ehya Regis; Hu,Xiang; Yu,Ai-Xi

doi:10.3892/or.2016.4553

Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-κB and MMP-9 activation

Authors:
- Wan-Rong Yi
- Zong-Huan Li
- Bai-Wen Qi
- Mendame Ehya Regis Ernest
- Xiang Hu
- Ai-Xi Yu
View Affiliations

Affiliations: Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 13, 2016 https://doi.org/10.3892/or.2016.4553
Pages: 2277-2285

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Isocitrate dehydrogenase 2 (IDH2) is a mitochondrial NADP-dependent isocitrate dehydrogenase. It is considered to be a novel tumor suppressor in several types of tumors. However, the role and related mechanism of IDH2 in osteosarcoma remain unknown. The expression and significance of IDH2 were investigated by immunohistochemistry in formalin-fixed paraffin sections from 44 osteosarcoma patients. IDH2 was downregulated via lentiviral vector‑mediated RNA interference (RNAi) in the Saos-2 and MG-63 human osteosarcoma cell lines. The effect of IDH2 downregulation on human osteosarcoma was studied in vitro by MTT, flow cytometry and invasion assays. Nuclear factor-κB (NF-κB) and matrix metalloproteinase-9 (MMP-9) assays were also used to study the likely molecular mechanism of IDH2 downregulation on the malignant progression of osteosarcoma cells. The results revealed that the expression of IDH2 was inversely correlated with pathological grade and metastasis in osteosarcoma. IDH2 downregulation promoted a pro-proliferative effect on the Saos-2 and MG-63 osteosarcoma cell lines. IDH2 downregulation accelerated cell cycle progression from S to G2/M phase. The pro-proliferative effect induced by IDH2 downregulation may be ascribed to increased NF-κB activity via IκBα phosphorylation. The invasive activity of osteosarcoma cells was also significantly promoted by IDH2 downregulation and may result from elevated MMP-9 activity. In conclusion, IDH2 downregulation may exacerbate malignant progression via increased NF-κB and MMP-9 activity and may implicate the potential biological importance of IDH2 targeting in osteosarcoma cells. Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-κB and MMP-9 activation.

View Figures

View References

1	Raymond AK and Jaffe N: Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective. Cancer Treat Res. 152:63–84. 2009. View Article : Google Scholar
2	Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res. 9:5442–5453. 2003.PubMed/NCBI
3	Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
4	Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-Year experience in 789 patients treated at a single institution. Cancer. 106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI
5	Memon AA, Chang JW, Oh BR and Yoo YJ: Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev. 29:249–255. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cancer Genome Atlas Research Network; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, et al: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
7	Ikota H, Nobusawa S, Arai H, Kato Y, Ishizawa K, Hirose T and Yokoo H: Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Brain Tumor Pathol. 32:237–244. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
9	Park SY, Lee SM, Shin SW and Park JW: Inactivation of mitochondrial NADP⁺-dependent isocitrate dehydrogenase by hypochlorous acid. Free Radic Res. 42:467–473. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jo SH, Son MK, Koh HJ, Lee SM, Song IH, Kim YO, Lee YS, Jeong KS, Kim WB, Park JW, et al: Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP⁺-dependent isocitrate dehydrogenase. J Biol Chem. 276:16168–16176. 2001. View Article : Google Scholar : PubMed/NCBI
11	Hu X, Liu Y, Qin C, Pan Z, Luo J, Yu A and Cheng Z: Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: In vitro and in vivo. Cancer Lett. 346:114–121. 2014. View Article : Google Scholar
12	Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, Luo J and Xu JH: The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 29:432010. View Article : Google Scholar : PubMed/NCBI
13	Kim SH, Yoo YH, Lee JH and Park JW: Mitochondrial NADP⁺-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells. Biochem Biophys Res Commun. 451:246–251. 2014. View Article : Google Scholar : PubMed/NCBI
14	Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, Park JW, Park DC, Song BJ, Veech RL, et al: Cytosolic NADP⁺-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem. 279:39968–39974. 2004. View Article : Google Scholar : PubMed/NCBI
15	Nakamura H: Thioredoxin and its related molecules: Update 2005. Antioxid Redox Signal. 7:823–828. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kirsch M and De Groot H: NAD(P)H, a directly operating antioxidant? FASEB J. 15:1569–1574. 2001. View Article : Google Scholar : PubMed/NCBI
17	Avery AM, Willetts SA and Avery SV: Genetic dissection of the phospholipid hydroperoxidase activity of yeast gpx3 reveals its functional importance. J Biol Chem. 279:46652–46658. 2004. View Article : Google Scholar : PubMed/NCBI
18	Nishikawa M: Reactive oxygen species in tumor metastasis. Cancer Lett. 266:53–59. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kim S, Kim SY, Ku HJ, Jeon YH, Lee HW, Lee J, Kwon TK, Park KM and Park JW: Suppression of tumorigenesis in mitochondrial NADP⁺-dependent isocitrate dehydrogenase knock-out mice. Biochim Biophys Acta. 1842:135–143. 2014. View Article : Google Scholar
20	Kim ES and Moon A: Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncol Lett. 9:897–902. 2015.PubMed/NCBI
21	Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K and Hirata M: The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol. 146:633–641. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl 1): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
23	Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H and Rosier RN: Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res. 312:40–50. 2006. View Article : Google Scholar
24	Andela VB, Sheu TJ, Puzas EJ, Schwarz EM, O'Keefe RJ and Rosier RN: Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. Biochem Biophys Res Commun. 297:237–241. 2002. View Article : Google Scholar : PubMed/NCBI
25	Han YP, Tuan TL, Wu H, Hughes M and Garner WL: TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci. 114:131–139. 2001.
26	Sun P, Mu Y and Zhang S: A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1. Tumour Biol. 35:12721–12727. 2014. View Article : Google Scholar : PubMed/NCBI
27	Park SL, Kim WJ and Moon SK: p21WAF1 mediates the IL-15-induced migration and invasion of human bladder cancer 5637 cells via the ERK1/2/NF-κB/MMP-9 pathway. Int Immunopharmacol. 22:59–65. 2014. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY and Yuan H: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 14:2762014. View Article : Google Scholar : PubMed/NCBI
29	Poudel B and Kim DK, Ki HH, Kwon YB, Lee YM and Kim DK: Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett. 7:215–218. 2014.
30	Wang IC, Chen YJ, Hughes DE, Ackerson T, Major ML, Kalinichenko VV, Costa RH, Raychaudhuri P, Tyner AL and Lau LF: FoxM1 regulates transcription of JNK1 to promote the G₁/S transition and tumor cell invasiveness. J Biol Chem. 283:20770–20778. 2008. View Article : Google Scholar : PubMed/NCBI
31	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
32	Xu J, Wu S and Shi X: Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 28:1621–1625. 2010. View Article : Google Scholar : PubMed/NCBI
33	Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer. 9:52010. View Article : Google Scholar : PubMed/NCBI
34	Luo Y, Liang F and Zhang ZY: PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry. 48:1838–1846. 2009. View Article : Google Scholar : PubMed/NCBI
35	Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH, Cheng SY and Zhang HZ: Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med. 13:567–575. 2007. View Article : Google Scholar : PubMed/NCBI
36	Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB and Grandis JR: Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res. 14:7682–7690. 2008. View Article : Google Scholar : PubMed/NCBI
37	Boye K, Grotterød I, Aasheim HC, Hovig E and Maelandsmo GM: Activation of NF-kappaB by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes. Int J Cancer. 123:1301–1310. 2008. View Article : Google Scholar : PubMed/NCBI
38	Huvos AG, Rosen G and Marcove RC: Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 101:14–18. 1977.PubMed/NCBI
39	Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer. 43:2163–2177. 1979. View Article : Google Scholar : PubMed/NCBI
40	Pessôa IA, Sagica FE, Anselmo NP, Brito JR and de Oliveira EH: IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil. Genet Mol Res. 14:6533–6542. 2015. View Article : Google Scholar : PubMed/NCBI
41	Waitkus MS, Diplas BH and Yan H: Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. Jul 16–2015.(Epub ahead of print). pii: nov136. PubMed/NCBI
42	Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA and Majeti R: Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 21:178–184. 2015. View Article : Google Scholar : PubMed/NCBI
43	Aref S, Kamel Areida el S, Abdel Aaal MF, Adam OM, El-Ghonemy MS, El-Baiomy MA and Zeid TA: Prevalence and clinical effect of IDH1 and IDH2 mutations among cytogenetically normal acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 15:550–555. 2015. View Article : Google Scholar : PubMed/NCBI
44	Liu WR, Tian MX, Jin L, Yang LX, Ding ZB, Shen YH, Peng YF, Zhou J, Qiu SJ, Dai Z, et al: High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. J Exp Clin Cancer Res. 33:322014. View Article : Google Scholar : PubMed/NCBI
45	Lv Q, Xing S, Li Z, Li J, Gong P, Xu X, Chang L, Jin X, Gao F, Li W, et al: Altered expression levels of IDH2 are involved in the development of colon cancer. Exp Ther Med. 4:801–806. 2012.PubMed/NCBI
46	Simeonidis S, Stauber D, Chen G, Hendrickson WA and Thanos D: Mechanisms by which IkappaB proteins control NF-kappaB activity. Proc Natl Acad Sci USA. 96:49–54. 1999. View Article : Google Scholar : PubMed/NCBI